2. Search Result
Search Result
Results for "

MMAF

" in MedChemExpress (MCE) Product Catalog:

49

Inhibitors & Agonists

3

Fluorescent Dye

3

Biochemical Assay Reagents

1

Peptides

3

Inhibitory Antibodies

2

Isotope-Labeled Compounds

1

Antibodies

5

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15579
    MMAF
    Maximum Cited Publications
    8 Publications Verification

    Monomethylauristatin F

    		 Microtubule/Tubulin ADC Payload Cancer
    MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .
    MMAF
  • HY-156225
    MMAF-OtBu

    		ADC Payload Cancer
    MMAF-OtBu (Example 2) is a modified MMAF (HY-15579 ). MMAF-OtBu can be used for synthesis of ADCs .
    MMAF-OtBu
  • HY-15579AS
    MMAF-d8 hydrochloride
    1 Publications Verification

    		 Microtubule/Tubulin ADC Payload Cancer
    MMAF-d8 (hydrochloride)e is a deuterated form of MMAF hydrochloride, which is a microtubule disrupting agent.
    MMAF-d8 hydrochloride
  • HY-79254
    MMAF intermediate 2

    		ADC Payload Cancer
    MMAF intermediate 2 is an intermediate for the synthesis of MMAF (HY-15579). MMAF (Monomethylauristatin F) is a potent inhibitor of tubulin polymerization and the cytotoxic (ADC Cytotoxin) component of classic antibody drug conjugates (ADCs), such as Vorsetuzumab mafodotin and SGN-CD19A .
    MMAF intermediate 2
  • HY-79253
    MMAF intermediate 1

    		ADC Payload Cancer
    MMAF intermediate 1 is an intermediate in the synthesis of MMAF (HY-15579). MMAF (Monomethylauristatin F) is a potent inhibitor of tubulin polymerization and the cytotoxic (ADC Cytotoxin) component of classic antibody drug conjugates (ADCs), such as Vorsetuzumab mafodotin and SGN-CD19A .
    MMAF intermediate 1
  • HY-15579A
    MMAF hydrochloride
    Maximum Cited Publications
    8 Publications Verification

    Monomethylauristatin F hydrochloride

    		 Microtubule/Tubulin ADC Payload Cancer
    MMAF (Monomethylauristatin F) hydrochloride is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF hydrochloride is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .
    MMAF hydrochloride
  • HY-15579B
    MMAF sodium
    Maximum Cited Publications
    8 Publications Verification

    Monomethylauristatin F sodium

    		 Microtubule/Tubulin ADC Payload Cancer
    MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .
    MMAF sodium
  • HY-W190923
    MMAF-methyl ester

    		ADC Payload Cancer
    MMAF-methyl ester is an ADC cytotoxin.
    MMAF-methyl ester
  • HY-15579BG
    MMAF sodium

    Monomethylauristatin F sodium

    		 Microtubule/Tubulin ADC Payload Cancer
    MMAF sodium GMP is a GMP grade MMAF (sodium) (HY-15579B). MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .
    MMAF sodium
  • HY-15579G
    MMAF

    Monomethylauristatin F

    		 Microtubule/Tubulin ADC Payload Cancer
    MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF (HY-15579). MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .
    MMAF
  • HY-79256
    MMAF-OMe
    1 Publications Verification

    Monomethyl auristatin F methyl ester

    		 ADC Payload Cancer
    MMAF-Ome, an antitubulin agent, is also an ADC cytotoxin. MMAF-Ome inhibits several tumor cell lines with IC50s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435/5T4, MDAMB361DYT2, MDAMB468, and Raji (5T4 -) cell lines, respectively.
    MMAF-OMe
  • HY-136287
    DBM-MMAF
    1 Publications Verification

    		 Drug-Linker Conjugates for ADC Cancer
    DBM-MMAF is a agent-linker conjugate composed of a potent antitubulin agent MMAF and a linker DBM to make antibody agent conjugate (ADC) .
    DBM-MMAF
  • HY-139326
    NHS-MMAF

    		Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    NHS-MMAF is a modified MMAF extracted from patent WO2012143499, intermediat 219. MMAF is a potent tubulin polymerization inhibitor and is used as a antitumor agent
    NHS-MMAF
  • HY-112786
    MC-Val-Cit-PAB-MMAF
    2 Publications Verification

    Vc-MMAF

    		 Drug-Linker Conjugates for ADC Cancer
    MC-Val-Cit-PAB-MMAF (Vc-MMAF) is a drug-linker conjugate for ADC by using the tubulin inhibitor, MMAF (HY-15579), linked via cathepsin cleavable MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB-MMAF shows antitumor activity .
    MC-Val-Cit-PAB-MMAF
  • HY-141594
    Modified MMAF

    		Microtubule/Tubulin Cancer
    Modified MMAF, an ADC cytotoxin, can be used in the synthesis of Antibody-drug Conjugate (ADC). Modified MMAF can be used for the targeted research of cancer .
    Modified MMAF
  • HY-170865
    OncoFAP-GlyPro-MMAF

    		Drug-Linker Conjugates for ADC Cancer
    OncoFAP-GlyPro-MMAF is a Drug-Linker Conjugate for ADC with potent antitumor activity. OncoFAP-GlyPro-MMAF consists of Monomethylauristatin F (HY-15579) and a linker. OncoFAP-GlyPro-MMAF can be used for synthesis of ADCs .
    OncoFAP-GlyPro-MMAF
  • HY-79255
    Fmoc-MMAF-OMe

    		ADC Payload Microtubule/Tubulin Cancer
    Fmoc-MMAF-OMe is an anticancer agent and tubulin polymerization inhibitor with an Fmoc protecting group. The active ingredient of Fmoc-MMAF-OMe, MMAF (HY-15579), is the cytotoxic (ADC Cytotoxin) component of classic antibody drug conjugates (ADCs) .
    Fmoc-MMAF-OMe
  • HY-145951
    Amidate-VC-PAB-MMAF

    		Drug-Linker Conjugates for ADC Cancer
    Amidate-VC-PAB-MMAF consists a cleavable ADC linker (Amidate-VC-PAB) and a potent tubulin polymerization inhibitor (MMAF). Amidate-VC-PAB-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs). Amidate-VC-PAB-MMAF reduces off-target cytotoxicity of ADCs .
    Amidate-VC-PAB-MMAF
  • HY-133492
    DBCO-PEG4-MMAF

    		Drug-Linker Conjugates for ADC Cancer
    DBCO-PEG4-MMAF is a agent-linker conjugate for ADC with potent antitumor activity by using the tubulin polymerization inhibitor, MMAF, linked via the cleavable linker DBCO-PEG4. DBCO-PEG4-MMAF is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DBCO-PEG4-MMAF
  • HY-101909
    Val-Cit-PAB-MMAF

    		Drug-Linker Conjugates for ADC Cancer
    Val-Cit-PAB-MMAF is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAF contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF (HY-15579)
    Val-Cit-PAB-MMAF
  • HY-44177
    Val-Cit-PAB-MMAF sodium

    		Drug-Linker Conjugates for ADC Cancer
    Val-Cit-PAB-MMAF sodium is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAF sodium contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF (HY-15579)
    Val-Cit-PAB-MMAF sodium
  • HY-128961
    MC-Alkyl-Hydrazine Modified MMAF

    		Drug-Linker Conjugates for ADC Cancer
    MC-Alkyl-Hydrazine Modified MMAF is a agent-linker conjugate for ADC with potent antitumor activity by using the Modified MMAF (a tubulin inhibitor), linked via the noncleavable MC-Alkyl-Hydrazine .
    MC-Alkyl-Hydrazine Modified MMAF
  • HY-128968
    PEG4-aminooxy-MMAF

    Amberstatin; AS269

    		 Microtubule/Tubulin Drug-Linker Conjugates for ADC Inflammation/Immunology Cancer
    PEG4-aminooxy-MMAF is a agent-linker conjugate for ADC with potent antitumor activity by using the potent antitubulin agent MMAF, linked via the noncleavable PEG4 .
    PEG4-aminooxy-MMAF
  • HY-128711
    MAL-di-EG-Val-Cit-PAB-MMAF

    		Drug-Linker Conjugates for ADC Cancer
    MAL-di-EG-Val-Cit-PAB-MMAF consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin polymerization blocker (MMAF, Monomethyl auristatin F) .
    MAL-di-EG-Val-Cit-PAB-MMAF
  • HY-141593
    Modified MMAF-C5-COOH

    		Drug-Linker Conjugates for ADC Cancer
    Modified MMAF-C5-COOH is a agent-linker conjugate for ADC .
    Modified MMAF-C5-COOH
  • HY-139325
    NHS-Modified MMAF

    		Drug-Linker Conjugates for ADC Others
    NHS-Modified MMAF (WO2012143499A2, intermediat 210) is an intermediate which can be used for producing the anti-mesothelin binder-agent conjugates (ADCs) .
    NHS-Modified MMAF
  • HY-130990
    DBCO-PEG4-Val-Cit-PAB-MMAF

    		Drug-Linker Conjugates for ADC Cancer
    DBCO-PEG4-Val-Cit-PAB-MMAF consists a cleavable 4 unit PEG ADC linker (DBCO-PEG4-Val-Cit-PAB) and a potent tubulin polymerization inhibitor (MMAF). DBCO-PEG4-Val-Cit-PAB-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-PEG4-Val-Cit-PAB-MMAF is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DBCO-PEG4-Val-Cit-PAB-MMAF
  • HY-139325A
    NHS-Modified MMAF TFA

    		Drug-Linker Conjugates for ADC Cancer
    NHS-Modified MMAF (intermediat 210) TFA is an intermediate which can be used for producing the anti-mesothelin binder-agent conjugates (ADCs) .
    NHS-Modified MMAF TFA
  • HY-164310
    TCO-PEG3-Glu-Val-Cit-PABC-MMAF

    		Microtubule/Tubulin Drug-Linker Conjugates for ADC Cancer
    TCO-PEG3-Glu-Val-Cit-PABC-MMAF is a linker-drug conjugate, which is consisted of a click pair TCO, a spacer PEG, a cleavable linker Glu-Val-Cit, a PBAC group and a cytotoxin MMAF (HY-15579). TCO-PEG3-Glu-Val-Cit-PABC-MMAF can be used for synthesis of dual drug ADC .
    TCO-PEG3-Glu-Val-Cit-PABC-MMAF
  • HY-156758
    Mal-PEG8-Val-Cit-PAB-MMAF

    		Drug-Linker Conjugates for ADC Cancer
    Mal-PEG8-Val-Cit-PAB-MMAF is a drug-linker conjugate for ADC. Mal-PEG8-Val-Cit-PAB-MMAF contains a cleavable ADC linker and a potent tubulin inhibitor MMAE (HY-15162) .
    Mal-PEG8-Val-Cit-PAB-MMAF
  • HY-155744
    Acetylene-PEG3-MMAF-OMe

    LCB14-0536

    		 Drug-Linker Conjugates for ADC Others
    Acetylene-PEG3-MMAF-OMe (LCB14-0536) is a protein-active agent conjugate. Acetylene-PEG3-MMAF-OMe can be recognized by isoprenoid transferase . Acetylene-PEG3-MMAF-OMe is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Acetylene-PEG3-MMAF-OMe
  • HY-153739
    N3-PEG3-VC-PAB-MMAF
    1 Publications Verification

    		 Drug-Linker Conjugates for ADC Cancer
    N3-PEG3-VC-PAB-MMAF (Comp T-88-5) is a drug-linker conjugate containing the ADC linker N3-PEG3-VC-PAB and the tubulin inhibitor MMAF . N3-PEG3-VC-PAB-MMAF is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    N3-PEG3-VC-PAB-MMAF
  • HY-131158
    DBCO-PEG3-Glu-VC-PABC-MMAF

    		ADC Linker Cancer
    DBCO-PEG3-Glu-VC-PABC-MMAF (compound s19b) is a cleavable PEG-based ADC linker that can be used in the synthesis of antibody-drug conjugates (ADCs) .
    DBCO-PEG3-Glu-VC-PABC-MMAF
  • HY-P99334
    Vorsetuzumab mafodotin

    Anti-Human CD70 Recombinant Antibody; SGN-75

    		 Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Cancer
    Vorsetuzumab mafodotin (SGN-75) is an Auristatin-based anti-CD70 antibody-drug conjugate (ADC). Vorsetuzumab mafodotin consists of a humanized monoclonal antibody, Vorsetuzumab and an ADC cytotoxin MMAF. Vorsetuzumab mafodotin has antineoplastic activity .
    Vorsetuzumab mafodotin
  • HY-W142140
    N-Methyl-DL-valine

    N-Methylvaline

    		 Amino Acid Derivatives Others
    N-Methyl-DL-valine is a valine derivant, is metabolized to cysteine, alanine, tyrosine, tryptophan, citric acid, and succinic acid in the sprout. N-Methyl-DL-valine involves in the modification of monomethyl auristatin F (MMAF), an anti-tubulin agent, makes it hydrophobic functionalization and increases cell permeability .
    N-Methyl-DL-valine
  • HY-171489
    Mal-VC-PAB-EDA-N-Ac-Calicheamicin

    		Drug-Linker Conjugates for ADC Cancer
    Mal-VC-PAB-EDA-N-Ac-Calicheamicin is a Drug-Linker Conjugate for ADC with potent antitumor activity. OncoFAP-GlyPro-MMAF consists of ADC toxin Calicheamicin (HY-19609) and a linker. OncoFAP-GlyPro-MMAF can be used for synthesis of ADC, PF-06647263 (HY-111965) .
    Mal-VC-PAB-EDA-N-Ac-Calicheamicin
  • HY-W250408
    Fmoc-NMe-Val-Val-Dil-Dap-OH

    		Drug-Linker Conjugates for ADC Cancer
    Fmoc-NMe-Val-Val-Dil-Dap-OH is an intermediate for preparing drug-linker conjugate MC-MMAF, which can be used for synthesis of ADC molecule .
    Fmoc-NMe-Val-Val-Dil-Dap-OH
  • HY-157080
    Dibromomaleimide-C5-COOH

    DBM-C5-COOH

    		 ADC Linker Cancer
    Dibromomaleimide-C5-COOH (DBM-C5-COOH) is a bifunctional dibromomaleimide (DBM) linker. Dibromomaleimide-C5-COOH can be used to connect MMAF and to synthesize ADC .
    Dibromomaleimide-C5-COOH
  • HY-P9980
    Belantamab

    GSK2857914

    		 ADC Antibody TNF Receptor Cancer
    Belantamab (GSK2857916) is a humanized IgG1 anti-BCMA/TNFRSF17 monoclonal antibody. Belantamab is linked to MMAF (HY-15579) through a non-cleavable ADC linker to synthesize the antibody-active molecule conjugate (ADC) Belantamab mafodotin (HY-P3239). After binding to BCMA on the surface of tumor cells, Belantamab mafodotin enters the cell through receptor-mediated endocytosis. After entering the cell, Belantamab mafodotin releases MMAF, blocks cell division by inhibiting tubulin polymerization, arrests the cell cycle and induces cell apoptosis. Belantamab can be used for the study of multiple myeloma, especially relapsed/refractory multiple myeloma .
    Belantamab
  • HY-15583
    Auristatin F

    		ADC Payload Microtubule/Tubulin Cancer
    Auristatin F is a potent cytotoxin in antibo-conjugated agents and an analogue of MMAF. Auristatin F is a potent microtubule inhibitor and vascular damaging agent (VDA). Auristatin F inhibits cell division by preventing tubulin aggregation.Auristatin F can be used in antibody-drug conjugates (ADC) .
    Auristatin F
  • HY-W142140A
    N-Methyl-DL-valine hydrochloride

    N-Methylvaline hydrochloride

    		 Amino Acid Derivatives Cancer
    N-Methyl-DL-valine (N-Methylvaline) hydrochloride is a valine derivant, is metabolized to cysteine, alanine, tyrosine, tryptophan, citric acid, and succinic acid in the sprout. N-Methyl-DL-valine hydrochloride involves in the modification of monomethyl auristatin F (MMAF), an anti-tubulin agent, makes it hydrophobic functionalization and increases cell permeability .
    N-Methyl-DL-valine hydrochloride
  • HY-15578G
    McMMAF

    Maleimidocaproyl monomethylauristatin F

    		 Drug-Linker Conjugates for ADC Cancer
    McMMAF GMP is a GMP grade McMMAF (HY-15578). McMMAF is a protective group (maleimidocaproyl)-conjugated MMAF, which is a potent tubulin polymerization inhibitor. McMMAF can be used as a agent-linker for antibody-drug conjugates (ADC). McMMAF is uncleavable, and must be internalized and degraded within a cell, releasing cysteine-McMMAF as the active agent .
    McMMAF
  • HY-15578
    McMMAF
    5 Publications Verification

    Maleimidocaproyl monomethylauristatin F

    		 Drug-Linker Conjugates for ADC Apoptosis Cancer
    McMMAF (Maleimidocaproyl monomethylauristatin F) is an active molecule linker for ADC, made by coupling the powerful microtubule inhibitor Monomethyl auristatin F (MMAF) with the protecting group maleimidocaproyl. McMMAF can be conjugated with anti-BCMA antibodies to form J6M0-mcMMAF, promoting apoptosis and inhibiting tumor growth .
    McMMAF
  • HY-15583S
    Auristatin F-d8

    		Isotope-Labeled Compounds ADC Payload Microtubule/Tubulin Cancer
    Auristatin F-d8 is deuterium labeled Auristatin F (HY-15583). Auristatin F is a potent cytotoxin in antibo-conjugated agents and an analogue of MMAF. Auristatin F is a potent microtubule inhibitor and vascular damaging agent (VDA). Auristatin F inhibits cell division by preventing tubulin aggregation.Auristatin F can be used in antibody-drug conjugates (ADC) .
    Auristatin F-d8
  • HY-150233
    Cys-McMMAF

    		Microtubule/Tubulin Cancer
    Cys-McMMAF is the released payload of AlMcMMAF, an anti-5T4 humanized A1 antibody conjugated to the microtubule disrupting MMAF (HY-15579) via a maleimidocaproyl linker. Cys-McMMAF has antitumor efficacy in two tumor mouse models (H1975 and MDA-MB-361-DYT2 models) .
    Cys-McMMAF
  • HY-164154
    ADC Control Human IgG1-vcMMAF

    		Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Cancer
    ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
    ADC Control Human IgG1-vcMMAF
  • HY-171682
    Anti-CCL2 (Carlumab)-McMMAF

    		Antibody-Drug Conjugates (ADCs) CCR Microtubule/Tubulin Apoptosis Cancer
    Anti-CCL2 (Carlumab)-McMMAF is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated to the protective group maleimidocaproyl and the tubulin inhibitor MMAF (HY-15579). The ADC toxic molecule and linker part are McMMAF (HY-15578). Anti-CCL2 (Carlumab)-McMMAF induces apoptosis and can be used in cancer research .
    Anti-CCL2 (Carlumab)-McMMAF
  • HY-171737
    Anti-SLC34A2 (Lifastuzumab)-McMMAF

    		Antibody-Drug Conjugates (ADCs) Sodium Channel Microtubule/Tubulin Apoptosis Cancer
    Anti-SLC34A2 (Lifastuzumab)-McMMAF is an antibody-drug conjugate (ADC) consisting of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab (HY-P99970) conjugated to the protective group maleimidocaproyl and the tubulin inhibitor MMAF (HY-15579). The ADC toxic molecule and linker part McMMAF (HY-15578). Anti-SLC34A2 (Lifastuzumab)-McMMAF induces apoptosis and can be used in cancer research .
    Anti-SLC34A2 (Lifastuzumab)-McMMAF
  • HY-145149
    Duostatin 5

    		ADC Payload Cancer
    Duostatin 5 is a ADC Cytotoxin designed based on MMAF (HY-15579) and can be used to synthesize ADCs. The preparation of Duostatin 5 has the advantages of fewer synthetic steps, simple operation, less difficulty in quality control, and more stable chemical synthesis process. Duostatin 5 can be linked to the antibody targeting 5T4 (ZV05) by cross-linking with interchain cysteines through a disubstituted C-Lock linker. Duostatin 5 is a click chemistry reagent. It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-driven alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups[1][2].
    Duostatin 5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: